TL;DR
Get everyday helpers delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
A study presented at a European dermatology meeting found higher rates of nail disorders, including detached nails, among GLP-1 receptor agonist users than among comparison participants with obesity or type 2 diabetes. The association weakened in adjusted analyses, and an analysis limited to new-onset nail problems found no difference, so the study does not establish that the drugs caused the changes.
A large study presented at the European Academy of Dermatology and Venereology meeting found that people taking GLP-1 receptor agonists reported more nail disorders, including onycholysis, or nail separation, than a comparison group with obesity and/or type 2 diabetes. The results show an association, not proof that the medications caused the changes: when researchers examined only nail problems that began after treatment started, they found no difference in onycholysis or discoloration between the groups.
The study compared 575 GLP-1 receptor agonist users with 1,329 people who had obesity and/or type 2 diabetes and had never used a GLP-1 drug. Participants were recruited in France, the United States, Brazil and Mexico. The comparison group was older on average—56.7 years, compared with 45.3 among drug users—while the sex distribution was approximately even in both groups.
In the reported results, 39.3% of GLP-1 users had onycholysis, compared with 8.7% of non-users, a 4.5-fold difference in prevalence. Nail discoloration, or dyschromia, was reported by 45.6% of users and 17.0% of non-users. Nail fragility and ridges or grooves were also more common among users. Overall, 66.3% of users and 52.8% of non-users reported some kind of nail disorder; the difference was statistically significant.
Researchers said the association persisted in analyses accounting for factors including age, sex, country and health conditions, though the estimates changed depending on which factors were included. Nearly half of GLP-1 users reported nail problems before starting treatment. When investigators focused on new-onset lesions, the difference in onycholysis and dyschromia disappeared. Study details supplied for this report do not include the full results of every adjusted analysis.
Nail Symptoms Need Careful Review
The findings may prompt clinicians and patients to pay attention to nail changes during GLP-1 treatment, but they do not support treating detached nails as an established medication side effect. The gap between the overall prevalence results and the new-onset analysis is central: some participants had nail problems before taking the drugs, and the study relied on information reported by participants rather than a dermatologist examining each person.
Study presenter Bianca Maria Piraccini said clinicians should ask whether nail abnormalities predated treatment or appeared after it began. The study’s outside commentator, Joe Tung of the University of Pittsburgh Medical Center, said the findings alone would not justify stopping an otherwise beneficial GLP-1 medication. Nail changes can have other causes, and people who notice them can seek assessment from a dermatologist.
nail health supplements for brittle nails
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How Researchers Read the Association
GLP-1 receptor agonists are used in the treatment of type 2 diabetes and obesity. The study addressed nail and hair changes reported during treatment, an area co-investigator Charles Taieb described as previously based largely on anecdotal reports. The researchers said they considered other possible explanations, including existing health conditions, prior nail problems and weight loss.
Piraccini argued that nail separation is not the same as surface changes sometimes associated with weight loss or reduced calorie intake, and said a direct drug effect was possible. Tung offered a more cautious interpretation: rapid weight loss or lower intake of protein and micronutrients could plausibly affect nails, while the survey design and pre-existing symptoms make it difficult to assign a cause. These are interpretations, not conclusions established by the comparison.
“These findings alone, however, would not justify stopping an otherwise beneficial GLP-1 medication for the appropriate patient.”
— Joe Tung, University of Pittsburgh Medical Center, who was not involved in the study
nail repair kits for damaged nails
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Cause Remains Unproven
The study does not establish whether GLP-1 drugs cause nail separation or discoloration. The new-onset analysis found no group difference, while broader analyses found higher prevalence among users, including after some adjustments. Investigators said they believe the true association may fall between those results, but that remains a hypothesis.
The comparison also has limitations: participants self-reported nail problems in an online survey, and the groups differed in age. Although the researchers accounted for several factors and said they considered possible alternative causes, the supplied study account does not provide enough detail to assess every adjustment or how nail conditions were independently verified. The size of any direct medication effect, if one exists, is still unknown.
dermatologist-recommended nail treatment
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Further Studies Are Planned
Piraccini said the findings would lead the researchers to conduct more studies. Further work would need to clarify when nail changes begin, assess them through clinical examination and distinguish possible medication effects from pre-existing conditions, weight changes and nutritional factors. No timeline or specific design for the next study was provided.
For now, the researchers’ practical suggestion is to document whether nail changes were present before treatment and when they appeared. Tung advised people with nail changes to consult a dermatologist and said the study alone is not a reason to stop a prescribed GLP-1 medication.
nail strengthener for fragile nails
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What is onycholysis?
Onycholysis is the separation of a fingernail or toenail from the nail bed. The study counted it among the nail disorders reported by participants.
Did the study prove GLP-1 drugs cause detached nails?
No. It found a higher prevalence of reported nail separation among GLP-1 users, but an analysis of new-onset nail lesions found no difference between users and non-users. The results show an association, not proof of causation.
How common was nail separation in the study?
Onycholysis was reported in 39.3% of 575 GLP-1 users and 8.7% of 1,329 non-users in the comparison group. The figures describe this study’s participants and should not be taken as an estimate of risk for every person taking these drugs.
Should someone stop taking a GLP-1 medication because of nail changes?
The study does not establish that the medication caused the changes. Outside commentator Joe Tung said these findings alone would not justify stopping an otherwise beneficial medication. People with nail changes can discuss them with a qualified clinician or dermatologist before making treatment decisions.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
